Sun Pharma Share Price: Specialty business is witnessing improved traction
Sun Pharma Specialty business is witnessing improved traction. Pick up in the US specialty business coupled with likely traction from a sturdy new product launch pipeline, would fuel the growth of the US business. Moreover, geographic expansion/increasing penetration for specialty portfolios, in markets other than the US, would also aid the growth of specialty portfolios. Healthy growth in chronic therapies along with new launches gaining traction and a possible improvement in acute therapies is likely to fuel growth in the domestic formulations business.
Sun Pharma’s leadership position in the chronics segment which is likely to sustain and the expected pick up in the recent launches would drive the growth in the domestic business: Reuters